stockrowArcutis Biotherapeutics, Inc. (ARQT) vs Dianthus Therapeutics, Inc. (DNTH)
- Arcutis Biotherapeutics, Inc. ARQT 25.55 −5.37%
- Dianthus Therapeutics, Inc. DNTH 86.43 +4.12%
Arcutis Biotherapeutics, Inc. and Dianthus Therapeutics, Inc. are both Biotechnology companies. Dianthus Therapeutics, Inc. is the larger, with a market value of $4.6B against $3.4B — 1.4× the size. Dianthus Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 119×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 60.0% against −11.7%. Arcutis Biotherapeutics, Inc. has the higher net margin (5.88% vs −7,436.5%) and the higher return on invested capital (23.5% vs −36.6%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 12 and Dianthus Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | ARQT | DNTH | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.18% | 100.00% | 65.16% |
| Operating margin | 6.91% | (8,683.89%) | 0.00% |
| Net margin | 5.88% | (7,436.50%) | 0.00% |
| Free cash flow margin | 11.74% | (6,469.87%) | 0.00% |
| Return on equity | 14.88% | (22.61%) | (50.12%) |
| Return on assets | 6.68% | (21.81%) | (45.60%) |
| Return on invested capital | 23.48% | (36.55%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack